[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346564-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346564-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","analytical-and-clinical-validation-of-cancermaster-an-automated-targeted-ngs-panel-for-tumor-only-precision-oncology","Analytical and clinical validation of CancerMaster - an automated targeted NGS panel, for tumor-only precision oncology","","CancerMaster is an in-house hybrid capture targeted NGS panel covering 524 key genes for multidimensional molecular profiling of solid tumors. The study establishes an asynchronous, parallel one-stop automated analysis pipeline with automated reporting and benchmarks analytical results using reference materials, including 100% reproducibility, 99% analytical sensitivity, and 94% accuracy. In 668 patients, the panel detects variants, CNVs, fusions, viral infections, MSI, TMB, and HLA typing, showing strong MSI–TMB correlation and high clinical actionability.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/analytical-and-clinical-validation-of-cancermaster-an-automated-targeted-ngs-panel-for-tumor-only-precision-oncology/346564/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/analytical-and-clinical-validation-of-cancermaster-an-automated-targeted-ngs-panel-for-tumor-only-precision-oncology/346564.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the CancerMaster panel cover and enable?","Question",{"text":63,"@type":64},"CancerMaster covers 524 key genes for multidimensional molecular profiling of solid tumors. It supports detection of genomic alterations such as SNVs/indels, CNVs, fusions, viral infection, MSI, TMB, and HLA typing with an automated reporting system.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How well does CancerMaster perform analytically?",{"text":68,"@type":64},"Using reference materials, CancerMaster showed 100% reproducibility, 99% analytical sensitivity, and 94% accuracy. Analytical performance for other biomarker classes like CNVs, fusions, MSI, TMB, and viral detection was also evaluated.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical findings were reported from the 668-patient cohort?",{"text":72,"@type":64},"In 668 patients, CancerMaster identified actionable mutations such as in TP53, KRAS, and PIK3CA, and CNVs such as ERBB2 amplification across gastric and colorectal cancers. MSI and TMB were strongly correlated across the cohort and within gastric and colorectal subgroups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346564,1790219783,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAnalytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology  \nJingmin Che1,7, Woo Sun Kwon1,7, Jaeyoung Kim2, ErkhembayarJadamba3, Hyo Jun Han4, Yuhnam Kim4, Choong-kun Lee1,5, Chan Hee Park1, Ye Jin Moon1,6, Han Byeol Mun1,6, Hyun Cheol Chung1,5 & Sun Young Rha1,5,6􀀍  \nWe developed a CancerMaster-targeted next generation sequencing (NGS) panel covering 524 key genes specifically designed for the multidimensional molecular profiling of solid tumors. We aimed to establish CancerMaster as an asynchronous and parallel one-stop automated analysis pipeline with a reporting system to overcome the delay in existing NGS approaches. This panel can detect common genomic alteration types, including single nucleotide variants/indels and copy number variants (CNVs), fusions, Epstein-Barr virus/human papillomavirus infection, microsatellite instability (MSI), tumor mutational burden (TMB) status, and human leukocyte antigen typing. Using reference materials, CancerMaster demonstrated 100% reproducibility, 99% analytical sensitivity, and high accuracy (94%) . Analytical performance for other biomarker classes—including CNVs, fusions, MSI, TMB, and viral detection—was evaluated separately. In a cohort of 668 patients, we identified actionable mutations, including inTP53, KRAS, and PIK3CA, and CNVs, e.g., ERBB2 amplification in gastric (n = 412) and colorectal (n = 66) cancers. MSI and TMB were strongly correlated in all patients (n = 668, r = 0.75;  \np \u003C 10− 15), with consistent results in the gastric (n = 412, r = 0.75; p \u003C 10− 15 ) and colorectal (n = 66,  \nr = 0.87; p \u003C 10− 15 ) cancer groups. Furthermore, directly comparing with the TruSight Oncology 500 (TSO500) panel, CancerMaster demonstrated high concordance while uniquely identifying certain clinically relevant alterations, including an ERBB2 missense mutation. Hence, the CancerMaster panel demonstrated high analytical performance and strong clinical potential for supporting clinical decisions regarding personalized cancer treatment.  \nKeywords Gastric cancer, Colorectal cancer, TMB, MSI, Precision oncology. comprehensive genomic profiling  \nThe identification of active genetic alterations is crucial for predicting cancer prognosis and making treatment decisions, especially for patients with treatment-refractory solid tumors. These genetic alterations provide potential therapeutic guidance for selecting cancer-specific or pan-cancer-targeted immune checkpoint inhibitor (ICI) therapies. KRAS, NRAS, and BRAF mutations are crucial for predicting therapeutic responsesin metastatic colorectal carcinoma1. ICIs are used for treating multiple cancers based on programmed deathligand 1 expression, microsatellite instability (MSI) or deficiency in mismatch repair (dMMR) genes, and tumor mutation burden (TMB)2,3. Next-generation sequencing (NGS) technologies, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), are highly sensitive and accurate for genetic variation assessment, promoting precision oncology based on tumor molecular signatures. Although WGS and WES offer comprehensive, sensitive, and accurate genetic variation assessments, they have several problems, such as higher costs, more complex and time-consuming data processing, and lower sequencing depth than targeted sequencing. A lower sequencing depth may lead to reduced resolution and lower ability to detect rare or low-  \n1Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea. 2Pharos iBio Co., Ltd, Seoul, Republic of Korea. 3Mogam Institute for Biomedical Research, Seoul, Republic of Korea.  \n4Celemics, Seoul, Republic of Korea. 5Division of Medical Oncology, Department of Internal Medicine,Yonsei Cancer Center, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. 6Brain Korea 21 PLUS P","cbCaicS5Dk29MBvU","https://ap.wps.com/l/cbCaicS5Dk29MBvU","pdf",2064085,11,"English","# Analytical and clinical validation of CancerMaster\n## Panel design and automated analysis pipeline\n## Analytical performance and biomarker coverage\n## Clinical cohort results and actionable alterations\n## Correlation between MSI and TMB\n## Comparison with TruSight Oncology 500 (TSO500)","[{\"question\":\"What does the CancerMaster panel cover and enable?\",\"answer\":\"CancerMaster covers 524 key genes for multidimensional molecular profiling of solid tumors. It supports detection of genomic alterations such as SNVs/indels, CNVs, fusions, viral infection, MSI, TMB, and HLA typing with an automated reporting system.\"},{\"question\":\"How well does CancerMaster perform analytically?\",\"answer\":\"Using reference materials, CancerMaster showed 100% reproducibility, 99% analytical sensitivity, and 94% accuracy. Analytical performance for other biomarker classes like CNVs, fusions, MSI, TMB, and viral detection was also evaluated.\"},{\"question\":\"What clinical findings were reported from the 668-patient cohort?\",\"answer\":\"In 668 patients, CancerMaster identified actionable mutations such as in TP53, KRAS, and PIK3CA, and CNVs such as ERBB2 amplification across gastric and colorectal cancers. MSI and TMB were strongly correlated across the cohort and within gastric and colorectal subgroups.\"}]","Analytical and clinical validation of CancerMaster - an automated targeted NGS panel, for tumor-only precision oncology | PDF",1790061989,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/184150fea0424828c3607bdd4a532654.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b954fb5518911e0e2f8014fa5848aee0.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98e7f9d88c2eecfec2ce231826427cd2.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02af22539144f6a8834ea7a01b35c7ff.webp",980,1287]